Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01118377 · ClinicalTrials.gov registry record · Phase 2
A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT01118377 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 45 participants.
The verdict
NCT01118377, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study evaluated the effect of capecitabine and concomitant radiation therapy in children with newly diagnosed brainstem gliomas.
Interventions
- DRUG Capecitabine
- RADIATION Radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-05 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01118377
The ClinicalTrials.gov registry entry for NCT01118377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT01118377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01118377 about?
NCT01118377 is a clinical study titled "A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas". This study evaluated the effect of capecitabine and concomitant radiation therapy in children with newly diagnosed brainstem gliomas.
What is the current status of trial NCT01118377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2007-05. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01118377?
The interventions under investigation include: Capecitabine (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01118377?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.